Search

A Bifidobacterium infantis strain was microencapsulated within a film-forming protein-carbohydrate-oil emulsion. This novel encapsulant incorporated prebiotics and substantially protected the bacterium during nonrefrigerated storage and gastrointestinal transit. The dried microcapsules were small (15 to 20 μm), had low water activity (0.2 to 0.3), and rapidly released the bacteria in simulated intestinal fluid. [ABSTRACT FROM AUTHOR]

The costs of developing a probiotic or prebiotic ingredient have always been substantial. Ingredient characterization, evaluation of technological and physiological properties, and demonstrations of safety and clinical efficacy require expensive research. The demanding regulatory requirements imposed by EFSA raise the bar even higher so that the costs of acquiring the necessary clinical evidence to support labeling of these food ingredients is approaching that of pharmaceuticals. In order to justify investment in such expensive clinical development, companies require certainty that they can gain a return on investment. Patenting can provide some protection but is not always possible to patent ingredients, and the period of protection is limited. All ingredients eventually face the prospect of commoditization once patents expire. Branding strategies offer one means of maintaining adequate product differentiation to protect market share and margins over the long term. [ABSTRACT FROM AUTHOR]

With the dramatic reductions in the cost and time involved in DNA sequencing, a new approach to characterisation of bacteria is emerging. It is based on a comparison of complete genome sequences of a number of members of the same species (pangenomics). Pangenomics opens an array of new opportunities for understanding and improving industrial starter cultures and probiotics. These include understanding the formation of texture and flavour in dairy products, understanding the functionality of probiotics as well as providing information that can be used for strain screening, strain improvement, safety assessments and process improvements. [Copyright &y& Elsevier]

Pigs were fed a freeze-dried probiotic (Bifidobacterium animalis CSCC 1941) plus a high-amylose maize starch (HAMS) and a fructooligosaccharide (FOS) separately or together. Fecal output and total and individual major short-chain fatty acid (SCFA) concentrations and excretion were higher and pH was lower with HAMS than with FOS relative to when they were fed a low-amylose maize starch (LAMS; control). Fecal bifidobacteria numbers and total excretion were equally higher during feeding of FOS or HAMS and highest with HAMS + FOS. When probiotic supplementation was stopped, bifidobacteria numbers declined rapidly when they were fed LAMS, more slowly with FOS or HAMS, and were maintained with HAMS + FOS. The data confirm that both HAMS and FOS are prebiotics and suggest that they act through different mechanisms and that they are most effective in combination. However only HAMS raises fecal SCFA. [ABSTRACT FROM AUTHOR]